Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Abstract

Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a mainstay for decades. An emerging body of evidence suggests that SCIg might also exhibit clinical efficacy in CIDP and MMN. This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context. We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients.

• Authors: Verena I Leussink, Hans-Peter Hartung, Bernd C Kieseier, Mark Stettner
• Journal: Therapeutic advances in neurological disorders (Ther Adv Neurol Disord) Vol. 9 Issue 4 Pg. 336-43 (Jul 2016) ISSN: 1756-2856 [Print] England
• PMID: 27366241 (Publication Type: Journal Article, Review)